StockMacro
Company, fund or insider

Help

Menu

MiniMed

$16.01 +43% in 6 monthsMarket cap $4.5B

MMED on XNAS, Health Care, MiniMed Group, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 17% to $843M, but losses reached $309M over 12 months while institutional holders rose 49%.

  • BadFree cash flow was negative $316M over the last 12 months
  • WatchShares up 35% in six months after falling 10% in one month

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 31 Jul 2026

While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
2,800
Website
minimed.com
Listed
Nasdaq, US
Last results
1 Sep 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 31 Jul 2026: revenue $843.0M, net income $0.
Quarter to 26 Jul 2024: revenue –, net income -$19.0MQuarter to 25 Oct 2024: revenue –, net income -$5.0MQuarter to 24 Jan 2025: revenue $687.0M, net income -$10.0MQuarter to 24 Jan 2025: revenue $687.0M, net income -$10.0MQuarter to 25 Apr 2025: revenue $724.0M, net income -$172.0MQuarter to 25 Apr 2025: revenue $724.0M, net income -$172.0MQuarter to 25 Jul 2025: revenue $723.0M, net income -$16.0MQuarter to 25 Jul 2025: revenue $723.0M, net income -$16.0MQuarter to 24 Oct 2025: revenue –, net income -$5.0MQuarter to 23 Jan 2026: revenue $790.0M, net income -$119.0MQuarter to 23 Jan 2026: revenue $790.0M, net income -$119.0MQuarter to 24 Apr 2026: revenue $837.0M, net income -$185.0MQuarter to 24 Apr 2026: revenue $837.0M, net income -$185.0MQuarter to 31 Jul 2026: revenue $843.0M, net income $0Quarter to 31 Jul 2026: revenue $843.0M, net income $0
26 Jul 2024RevenueNet incomeNet losstallest bar $843.0M31 Jul 2026
See the numbers
Quarter toRevenueNet income
31 Jul 2026$843.0M$0
24 Apr 2026$837.0M-$185.0M
23 Jan 2026$790.0M-$119.0M
24 Oct 2025–-$5.0M
25 Jul 2025$723.0M-$16.0M
25 Apr 2025$724.0M-$172.0M
24 Jan 2025$687.0M-$10.0M
25 Oct 2024–-$5.0M
26 Jul 2024–-$19.0M
Fundamentals, 12 months to 31 Jul 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $3.2B –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$309.0M -$206.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.22 –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 53.9% – 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -5.3% – -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -9.6% – -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -8.6% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$316.0M –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $207.0M $9.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$207.0M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $12.87
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.4 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.3 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.2 2.8

Latest = 12 months to 31 Jul 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
MiniMedMMED (this company) $4.5Bloss1.4–-9.6%
ICU MedicalICUI $4.3B71.52.0-5.9%2.8%
HeartflowHTFL $4.1Bloss17.2+47%-33.1%
Merit Medical SystemsMMSI $5.1B31.63.1+9.1%9.9%
HaemoneticsHAE $5.5B52.74.0+4.1%7.5%
Pulse BiosciencesPLSE $3.4Blossover 999+1637%–

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+17%

$843.0M vs $723.0M (quarter ended 31 Jul 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-23%

$41.0M vs $53.0M (quarter ended 31 Jul 2026)

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+49%

145 13F filers vs 97

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

21%

58.2M shares held by 13F filers (30 Sep 2026) of 281.3M outstanding (3 Sep 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

3.5%

9.8M shares sold short (30 Oct 2026) of 281.3M outstanding (3 Sep 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

9.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-53%

20.7M shares sold short in the report before, 9.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

18%

18% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 49%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

148

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$330K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

29

29 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

9.7×

29 articles in the last 7 days; its usual week has 3.

Price $16.01 on 20 Nov 2026, -13% over 12 months (12-month range $10.80 to $23.84)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Revenue per quarter. Revenue $843.0M in the latest quarter, +17% on a year earlier.
Capital spending per quarter. Capital spending $41.0M in the latest quarter, -23% on a year earlier.
Institutional holders (13F filers). 145 13F filers reported holding it in the latest 13F quarter, +159% on a year earlier.
Lobbying spend. Lobbying spend: $330K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: insider net buying (open market), h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
16 Oct 20268-K and other filingsDirector or officer change
5 Aug 20268-K and other filingsDirector or officer change
29 Jun 20268-K and other filingsDirector or officer change
16 Jun 2026Lobbying filingnew lobbying registration (MEHLMAN CONSULTING, INC.)
18 May 20268-K and other filingsDirector or officer change
17 Apr 2026Lobbying filingnew lobbying registration (in-house)
17 Apr 2026Sharp changeFirst lobbying registration: first lobbying registration: MINIMED GROUP, INC.: new lobbying registration (in-house)
27 Mar 20268-K and other filingsDirector or officer change
9 Mar 20268-K and other filingsDirector or officer change
9 Mar 20268-K and other filingsCompleted an acquisition or asset sale
9 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Feb 20268-K and other filingsRegistered new securities for sale (S-1)
24 Feb 20268-K and other filingsRegistered new securities for sale (S-1)
23 Jan 20268-K and other filingsRegistered new securities for sale (S-1)
19 Dec 20258-K and other filingsRegistered new securities for sale (S-1)
Revenue per quarter
Quarter ended 24 Jan 2025: $687.0M; public on 18 Apr 2026
Quarter ended 25 Apr 2025: $724.0M; public on 30 Jun 2026
Quarter ended 25 Jul 2025: $723.0M; public on 9 Sep 2026
Quarter ended 23 Jan 2026: $790.0M, +15% on a year earlier; public on 18 Apr 2026
Quarter ended 24 Apr 2026: $837.0M, +16% on a year earlier; public on 30 Jun 2026
Quarter ended 31 Jul 2026: $843.0M, +17% on a year earlier; public on 9 Sep 2026
Capital spending per quarter
Quarter ended 25 Apr 2025: $57.0M; public on 30 Jun 2026
Quarter ended 25 Jul 2025: $53.0M; public on 9 Sep 2026
Quarter ended 24 Apr 2026: $56.0M, -1.8% on a year earlier; public on 30 Jun 2026
Quarter ended 31 Jul 2026: $41.0M, -23% on a year earlier; public on 9 Sep 2026
Institutional holders (13F filers)
31 Mar 2026 report: 56; public on 15 May 2026
30 Jun 2026 report: 97; public on 14 Aug 2026
30 Sep 2026 report: 145; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2026: $80K published
Quarter from 1 Jul 2026: $80K published
Quarter from 1 Oct 2026: $170K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is cash and cash equivalents at period end at $207.0M (31 Jul 2026), 19× its normal quarter; higher than 88% of its own history.
  • Revenue per quarter: Revenue $843.0M in the latest quarter, +17% on a year earlier.
  • Capital spending per quarter: Capital spending $41.0M in the latest quarter, -23% on a year earlier.
  • Institutional holders (13F filers): 145 13F filers reported holding it in the latest 13F quarter, +159% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

145 institutions reported shares at the end of Q3 2026, 21% of the shares outstanding; 63 opened a position, 16 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Massachusetts Financial Services Co9.4M3.35%$183.4M+1.1M+13%
T. Rowe Price Associates Inc4.0M1.42%+4.0M169 times as many
Frontier Capital Management Co LLC3.5M1.23%$67.3MNew+3.5M
FMR LLC (Fidelity)3.4M1.21%$66.3M+2.3M+215%
UBS Group AG2.7M0.97%$53.3M+2.3M+562%
BlackRock, Inc.2.1M0.75%$41.2M+117K+5.9%
ExodusPoint Capital Management, LP2.0M0.71%$39.1M+569K+40%
Healthcare of Ontario Pension Plan Trust Fund1.7M0.61%$33.5M+1.3M+359%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1.7M0.59%$32.2MNew+1.7M
Rock Springs Capital Management LP1.6M0.57%$31.2M+85K+5.6%

Company events

All 12 company events

In 12 months: 6 director or officer changes, 4 share registrations, 1 major agreement, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
16 Oct 2026Director or officer changeSame filing: change of control8-K
5 Aug 2026Director or officer change8-K
29 Jun 2026Director or officer change8-K
18 May 2026Director or officer change8-K
27 Mar 2026Director or officer change8-K
9 Mar 2026Director or officer change; Signed a major agreement; Completed an acquisition or asset saleSame filing: took on new debt, sold shares privately, changed shareholder rights, changed its bylaws or fiscal year8-K
27 Feb 2026Registered new securities for sale (S-1)S-1/A
24 Feb 2026Registered new securities for sale (S-1)S-1/A

148 open postings; careers site tracked since 21 Nov 2026. Most in Customer success & support 9%, Finance & accounting 8%, Test, quality & reliability 8%, Corporate IT 7%.

PostedJobLocation
21 Nov 2026or earlierInsurance Collections SMEPune, Maharashtra, India
21 Nov 2026or earlierSr IT Technologist - CCaas, Cisco UCCE, NICE CXoneCorporate ITPune, Maharashtra, India
21 Nov 2026or earlierSAP PP QM Senior Business AnalystOperations & administrationPune, Maharashtra, India
21 Nov 2026or earlierCredit & Collections Senior AnalystMadrid, Spain
21 Nov 2026or earlierSenior Clinical Data EngineerData & analyticsNot stated
21 Nov 2026or earlierPatient Services RepresentativeWatford, Hertfordshire, United Kingdom
21 Nov 2026or earlierIT Technologist - Clinical Trial Technology Specialist (CTMS, eTMF)Corporate ITPune, Maharashtra, India
21 Nov 2026or earlierSenior Customer Marketing SpecialistMarketing & communicationsVirtual, Hertfordshire, United Kingdom

Reported lobbying spend: $170K in Q3 2026, $80K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
15 May 2026NewMehlman Consulting, Inc.for Minimed Group, Inc.Issues related to medical device access and coverage.Health issues, Medicare/MedicaidFiling
6 Mar 2026NewMinimed Group, Inc.its own lobbyistsIssues related to diabetes care and devices.Health issuesFiling

The 5 newest of 265 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 16 Oct 2026Filings record

    Director or officer change

  2. 5 Aug 2026Filings record

    Director or officer change

  3. 29 Jun 2026Filings record

    Director or officer change

  4. 16 Jun 2026Lobbying record

    MINIMED GROUP, INC.: new lobbying registration (MEHLMAN CONSULTING, INC.) (dated 15 May 2026)

  5. 18 May 2026Filings record

    Director or officer change

  6. 17 Apr 2026Lobbying change

    registered for federal lobbying for the first time in our data (In-House).

    See the evidence (1 source record)
    Source coverage starts
    4 Apr 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  7. 17 Apr 2026Lobbying record

    MINIMED GROUP, INC.: new lobbying registration (in-house) (dated 6 Mar 2026)

  8. 27 Mar 2026Filings record

    Director or officer change

  9. 9 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 9 Mar 2026Filings record

    Director or officer change

  11. 9 Mar 2026Filings record

    Completed an acquisition or asset sale

  12. 27 Feb 2026Filings record

    Registered new securities for sale (S-1)

  13. 24 Feb 2026Filings record

    Registered new securities for sale (S-1)

  14. 23 Jan 2026Filings record

    Registered new securities for sale (S-1)

  15. 19 Dec 2025Filings record

    Registered new securities for sale (S-1)

Not listed: 7 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0002062583
Ticker
MMED
Domain
minimed.com
Hq location
CA|NORTHRIDGE|91325 (1 unverified)
Lobbying client
minimed group
Name
Companion Medical, Inc, Diabeter Center Amsterdam BV, Diabeter Nederland BV, Kangaroo US HoldCo, Inc and 32 more
  • Federal lobbying disclosures (LDA)2 records, 9 data points6 Mar 2026 to 30 Sep 2026
  • SEC Form 13F institutional holdings27 data points31 Mar 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)18 records19 Dec 2025 to 16 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)123 data points28 Apr 2023 to 3 Sep 2026
  • FINRA short interest (twice monthly)47 data points13 Mar 2026 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)362 data points6 Mar 2026 to 20 Nov 2026